Option chain shows key data for Greenwich LifeSciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Greenwich LifeSciences.

Greenwich LifeSciences (NASDAQ:GLSI) Stock, Option Chain

Greenwich LifeSciences

Greenwich LifeSciences, Inc. - Common stock

Overview

News

Earnings

Analyst Ratings

Insider Trades

Short Interest

Stock Report

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Comments

Greenwich LifeSciences Option Chain

No option chain data available. Please try again later